ABSTRACT Hepatobiliary syndrome (HBS) represents a significant challenge in farmed freshwater fish. While curcumin has emerged as a promising therapeutic candidate for HBS management, its clinical application remains constrained by poor solubility and low bioavailability. To overcome these limitations, a novel curcumin‐loaded lipid‐based solution (CUR‐LS) was developed, characterized by optimal physicochemical properties including minimal particle size (15.73 ± 0.68 nm), exceptional encapsulation efficiency (96.77 ± 0.45%) and stable nanomicelle formation in aqueous media, with transmission electron microscopy (TEM) analysis confirming uniform dispersion and spontaneous self‐assembly capability. Pharmacokinetic evaluation in grass carp ( Ctenopharyngodon idella ) demonstrated that the CUR‐LS significantly enhanced key parameters, including maximum plasma concentration ( C max ) and area under the concentration‐time curve (AUC 0–t ), achieving a 5.72‐fold improvement in relative bioavailability compared to conventional curcumin suspension. In grass carp with CCl 4 ‐induced liver injury, CUR‐LS supplementation (15–60 mg/kg body weight) exhibited hepatoprotective effects by significantly reducing serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, along with ameliorating histopathological damage. This study demonstrates that CUR‐LS enhances curcumin bioavailability and hepatoprotective efficacy in grass carp, providing a scientific basis for its further evaluation in aquaculture.
ZHANG et al. (Wed,) studied this question.